cloudfront

Report Detail



Pharma & Healthcare2018-2023 Global Performance Enhancing Drugs Consumption Market Report

  • RnM2475761
  • |
  • 29 August, 2018
  • |
  • Global
  • |
  • 133 pages
  • |
  • LPI(LP Information)
  • |
  • Pharma & Healthcare

2018-2023 Global Performance Enhancing Drugs Consumption Market Report

Table of Contents

    2018-2023 Global Performance Enhancing Drugs Consumption Market Report

      1 Scope of the Report

      • 1.1 Market Introduction
      • 1.2 Research Objectives
      • 1.3 Years Considered
      • 1.4 Market Research Methodology
      • 1.5 Economic Indicators
      • 1.6 Currency Considered

      2 Executive Summary

      • 2.1 World Market Overview
        • 2.1.1 Global Performance Enhancing Drugs Consumption 2013-2023
        • 2.1.2 Performance Enhancing Drugs Consumption CAGR by Region
      • 2.2 Performance Enhancing Drugs Segment by Type
        • 2.2.1 Ergogenic Aids
        • 2.2.2 Nootropic
      • 2.3 Performance Enhancing Drugs Consumption by Type
        • 2.3.1 Global Performance Enhancing Drugs Consumption Market Share by Type (2013-2018)
        • 2.3.2 Global Performance Enhancing Drugs Revenue and Market Share by Type (2013-2018)
        • 2.3.3 Global Performance Enhancing Drugs Sale Price by Type (2013-2018)
      • 2.4 Performance Enhancing Drugs Segment by Application
        • 2.4.1 Athletes
        • 2.4.2 Body Builders
        • 2.4.3 Students
        • 2.4.4 Militaries
      • 2.5 Performance Enhancing Drugs Consumption by Application
        • 2.5.1 Global Performance Enhancing Drugs Consumption Market Share by Application (2013-2018)
        • 2.5.2 Global Performance Enhancing Drugs Value and Market Share by Application (2013-2018)
        • 2.5.3 Global Performance Enhancing Drugs Sale Price by Application (2013-2018)

      3 Global Performance Enhancing Drugs by Players

      • 3.1 Global Performance Enhancing Drugs Sales Market Share by Players
        • 3.1.1 Global Performance Enhancing Drugs Sales by Players (2016-2018)
        • 3.1.2 Global Performance Enhancing Drugs Sales Market Share by Players (2016-2018)
      • 3.2 Global Performance Enhancing Drugs Revenue Market Share by Players
        • 3.2.1 Global Performance Enhancing Drugs Revenue by Players (2016-2018)
        • 3.2.2 Global Performance Enhancing Drugs Revenue Market Share by Players (2016-2018)
      • 3.3 Global Performance Enhancing Drugs Sale Price by Players
      • 3.4 Global Performance Enhancing Drugs Manufacturing Base Distribution, Sales Area, Product Types by Players
        • 3.4.1 Global Performance Enhancing Drugs Manufacturing Base Distribution and Sales Area by Players
        • 3.4.2 Players Performance Enhancing Drugs Products Offered
      • 3.5 Market Concentration Rate Analysis
        • 3.5.1 Competition Landscape Analysis
        • 3.5.2 Concentration Ratio (CR3, CR5 and CR10) (2016-2018)
      • 3.6 New Products and Potential Entrants
      • 3.7 Mergers & Acquisitions, Expansion

      4 Performance Enhancing Drugs by Regions

      • 4.1 Performance Enhancing Drugs by Regions
        • 4.1.1 Global Performance Enhancing Drugs Consumption by Regions
        • 4.1.2 Global Performance Enhancing Drugs Value by Regions
      • 4.2 Americas Performance Enhancing Drugs Consumption Growth
      • 4.3 APAC Performance Enhancing Drugs Consumption Growth
      • 4.4 Europe Performance Enhancing Drugs Consumption Growth
      • 4.5 Middle East & Africa Performance Enhancing Drugs Consumption Growth

      5 Americas

      • 5.1 Americas Performance Enhancing Drugs Consumption by Countries
        • 5.1.1 Americas Performance Enhancing Drugs Consumption by Countries (2013-2018)
        • 5.1.2 Americas Performance Enhancing Drugs Value by Countries (2013-2018)
      • 5.2 Americas Performance Enhancing Drugs Consumption by Type
      • 5.3 Americas Performance Enhancing Drugs Consumption by Application
      • 5.4 United States
      • 5.5 Canada
      • 5.6 Mexico
      • 5.7 Key Economic Indicators of Few Americas Countries

      6 APAC

      • 6.1 APAC Performance Enhancing Drugs Consumption by Countries
        • 6.1.1 APAC Performance Enhancing Drugs Consumption by Countries (2013-2018)
        • 6.1.2 APAC Performance Enhancing Drugs Value by Countries (2013-2018)
      • 6.2 APAC Performance Enhancing Drugs Consumption by Type
      • 6.3 APAC Performance Enhancing Drugs Consumption by Application
      • 6.4 China
      • 6.5 Japan
      • 6.6 Korea
      • 6.7 Southeast Asia
      • 6.8 India
      • 6.9 Australia
      • 6.10 Key Economic Indicators of Few APAC Countries

      7 Europe

      • 7.1 Europe Performance Enhancing Drugs by Countries
        • 7.1.1 Europe Performance Enhancing Drugs Consumption by Countries (2013-2018)
        • 7.1.2 Europe Performance Enhancing Drugs Value by Countries (2013-2018)
      • 7.2 Europe Performance Enhancing Drugs Consumption by Type
      • 7.3 Europe Performance Enhancing Drugs Consumption by Application
      • 7.4 Germany
      • 7.5 France
      • 7.6 UK
      • 7.7 Italy
      • 7.8 Russia
      • 7.9 Spain
      • 7.10 Key Economic Indicators of Few Europe Countries

      8 Middle East & Africa

      • 8.1 Middle East & Africa Performance Enhancing Drugs by Countries
        • 8.1.1 Middle East & Africa Performance Enhancing Drugs Consumption by Countries (2013-2018)
        • 8.1.2 Middle East & Africa Performance Enhancing Drugs Value by Countries (2013-2018)
      • 8.2 Middle East & Africa Performance Enhancing Drugs Consumption by Type
      • 8.3 Middle East & Africa Performance Enhancing Drugs Consumption by Application
      • 8.4 Egypt
      • 8.5 South Africa
      • 8.6 Israel
      • 8.7 Turkey
      • 8.8 GCC Countries

      9 Market Drivers, Challenges and Trends

      • 9.1 Market Drivers and Impact
        • 9.1.1 Growing Demand from Key Regions
        • 9.1.2 Growing Demand from Key Applications and Potential Industries
      • 9.2 Market Challenges and Impact
      • 9.3 Market Trends

      10 Marketing, Distributors and Customer

      • 10.1 Sales Channel
        • 10.1.1 Direct Marketing
        • 10.1.2 Indirect Marketing
      • 10.2 Performance Enhancing Drugs Distributors
      • 10.3 Performance Enhancing Drugs Customer

      11 Global Performance Enhancing Drugs Market Forecast

      • 11.1 Global Performance Enhancing Drugs Consumption Forecast (2018-2023)
      • 11.2 Global Performance Enhancing Drugs Forecast by Regions
        • 11.2.1 Global Performance Enhancing Drugs Forecast by Regions (2018-2023)
        • 11.2.2 Global Performance Enhancing Drugs Value Forecast by Regions (2018-2023)
        • 11.2.3 Americas Consumption Forecast
        • 11.2.4 APAC Consumption Forecast
        • 11.2.5 Europe Consumption Forecast
        • 11.2.6 Middle East & Africa Consumption Forecast
      • 11.3 Americas Forecast by Countries
        • 11.3.1 United States Market Forecast
        • 11.3.2 Canada Market Forecast
        • 11.3.3 Mexico Market Forecast
        • 11.3.4 Brazil Market Forecast
      • 11.4 APAC Forecast by Countries
        • 11.4.1 China Market Forecast
        • 11.4.2 Japan Market Forecast
        • 11.4.3 Korea Market Forecast
        • 11.4.4 Southeast Asia Market Forecast
        • 11.4.5 India Market Forecast
        • 11.4.6 Australia Market Forecast
      • 11.5 Europe Forecast by Countries
        • 11.5.1 Germany Market Forecast
        • 11.5.2 France Market Forecast
        • 11.5.3 UK Market Forecast
        • 11.5.4 Italy Market Forecast
        • 11.5.5 Russia Market Forecast
        • 11.5.6 Spain Market Forecast
      • 11.6 Middle East & Africa Forecast by Countries
        • 11.6.1 Egypt Market Forecast
        • 11.6.2 South Africa Market Forecast
        • 11.6.3 Israel Market Forecast
        • 11.6.4 Turkey Market Forecast
        • 11.6.5 GCC Countries Market Forecast
      • 11.7 Global Performance Enhancing Drugs Forecast by Type
      • 11.8 Global Performance Enhancing Drugs Forecast by Application

      12 Key Players Analysis

      • 12.1 Taj Pharmaceuticals
        • 12.1.1 Company Details
        • 12.1.2 Performance Enhancing Drugs Product Offered
        • 12.1.3 Taj Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.1.4 Main Business Overview
        • 12.1.5 Taj Pharmaceuticals News
      • 12.2 Balkan Pharmaceuticals
        • 12.2.1 Company Details
        • 12.2.2 Performance Enhancing Drugs Product Offered
        • 12.2.3 Balkan Pharmaceuticals Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.2.4 Main Business Overview
        • 12.2.5 Balkan Pharmaceuticals News
      • 12.3 Bayer
        • 12.3.1 Company Details
        • 12.3.2 Performance Enhancing Drugs Product Offered
        • 12.3.3 Bayer Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.3.4 Main Business Overview
        • 12.3.5 Bayer News
      • 12.4 AstraZeneca
        • 12.4.1 Company Details
        • 12.4.2 Performance Enhancing Drugs Product Offered
        • 12.4.3 AstraZeneca Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.4.4 Main Business Overview
        • 12.4.5 AstraZeneca News
      • 12.5 Novo Nordisk
        • 12.5.1 Company Details
        • 12.5.2 Performance Enhancing Drugs Product Offered
        • 12.5.3 Novo Nordisk Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.5.4 Main Business Overview
        • 12.5.5 Novo Nordisk News
      • 12.6 BrainAlert
        • 12.6.1 Company Details
        • 12.6.2 Performance Enhancing Drugs Product Offered
        • 12.6.3 BrainAlert Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.6.4 Main Business Overview
        • 12.6.5 BrainAlert News
      • 12.7 Douglas Laboratories
        • 12.7.1 Company Details
        • 12.7.2 Performance Enhancing Drugs Product Offered
        • 12.7.3 Douglas Laboratories Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.7.4 Main Business Overview
        • 12.7.5 Douglas Laboratories News
      • 12.8 Onnit Labs
        • 12.8.1 Company Details
        • 12.8.2 Performance Enhancing Drugs Product Offered
        • 12.8.3 Onnit Labs Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.8.4 Main Business Overview
        • 12.8.5 Onnit Labs News
      • 12.9 Eli Lilly And Company
        • 12.9.1 Company Details
        • 12.9.2 Performance Enhancing Drugs Product Offered
        • 12.9.3 Eli Lilly And Company Performance Enhancing Drugs Sales, Revenue, Price and Gross Margin (2016-2018)
        • 12.9.4 Main Business Overview
        • 12.9.5 Eli Lilly And Company News

      13 Research Findings and Conclusion

      In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Performance Enhancing Drugs market for 2018-2023.

      Performance-enhancing drugs (PED), are substances that are used to improve any form of activity performance in humans.
      A well-known example of PED involves doping in sport, where banned physical performance–enhancing drugs are used by athletes and bodybuilders. Athletic performance-enhancing substances are sometimes referred to as ergogenic aids. Cognitive performance-enhancing drugs, commonly called nootropics, are sometimes used by students to improve academic performance. Performance-enhancing substances are also used by military personnel to enhance combat performance.
      Over the next five years, LPI(LP Information) projects that Performance Enhancing Drugs will register a xx% CAGR in terms of revenue, reach US$ xx million by 2023, from US$ xx million in 2017.

      This report presents a comprehensive overview, market shares, and growth opportunities of Performance Enhancing Drugs market by product type, application, key manufacturers and key regions.

      To calculate the market size, LP Information considers value and volume generated from the sales of the following segments:

      Segmentation by product type:
      Ergogenic Aids
      Nootropic
      Segmentation by application:
      Athletes
      Body Builders
      Students
      Militaries

      This report also splits the market by region:
      Americas
      United States
      Canada
      Mexico
      Brazil
      APAC
      China
      Japan
      Korea
      Southeast Asia
      India
      Australia
      Europe
      Germany
      France
      UK
      Italy
      Russia
      Spain
      Middle East & Africa
      Egypt
      South Africa
      Israel
      Turkey
      GCC Countries

      The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report:
      Taj Pharmaceuticals
      Balkan Pharmaceuticals
      Bayer
      AstraZeneca
      Novo Nordisk
      BrainAlert
      Douglas Laboratories
      Onnit Labs
      Eli Lilly And Company

      In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key manufacturers and the market as a whole. It also analyzes key emerging trends and their impact on present and future development.

      Research objectives
      To study and analyze the global Performance Enhancing Drugs consumption (value & volume) by key regions/countries, product type and application, history data from 2013 to 2017, and forecast to 2023.
      To understand the structure of Performance Enhancing Drugs market by identifying its various subsegments.
      Focuses on the key global Performance Enhancing Drugs manufacturers, to define, describe and analyze the sales volume, value, market share, market competition landscape, SWOT analysis and development plans in next few years.
      To analyze the Performance Enhancing Drugs with respect to individual growth trends, future prospects, and their contribution to the total market.
      To share detailed information about the key factors influencing the growth of the market (growth potential, opportunities, drivers, industry-specific challenges and risks).
      To project the consumption of Performance Enhancing Drugs submarkets, with respect to key regions (along with their respective key countries).
      To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
      To strategically profile the key players and comprehensively analyze their growth strategies.




      Summary:
      Get latest Market Research Reports on Performance Enhancing Drugs . Industry analysis & Market Report on Performance Enhancing Drugs is a syndicated market report, published as 2018-2023 Global Performance Enhancing Drugs Consumption Market Report. It is complete Research Study and Industry Analysis of Performance Enhancing Drugs market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.


      REPORT YOU MIGHT BE INTERESTED

      Purchase this Report

      $4,660.00
      $6,990.00
      $9,320.00
      3,129.19
      4,693.79
      6,258.38
      4,288.13
      6,432.20
      8,576.26
      564,512.40
      846,768.60
      1,129,024.80
      309,020.44
      463,530.67
      618,040.89
      Credit card Logo

      Related Reports


      Reason to Buy

      Request for Sample of this report